Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions.
active surveillance
geographic variation
low-risk prostate cancer
radiation therapy
radical prostatectomy
watchful waiting
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
12
2020
accepted:
24
02
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Substantial geographic variation in healthcare practices exist. Active surveillance (AS) has emerged as a critical tool in the management of men with low-risk prostate cancer. Whether there have been regional differences in adoption is largely unknown. The SEER "Prostate with Watchful Waiting Database" was used to identify patients diagnosed with localized low-risk prostate cancer and managed with AS across US census regions between 2010 and 2016. Multivariable logistic regression models were used to determine the impact of region on undergoing AS and factors associated with AS use within each US census region. Between 2010 and 2016, the proportion of men managed with AS increased from 20.8% to 55.9% in the West, 11.5% to 50.0% in Northeast, 9.9% to 43.4% in the South and 15.1% to 56.2% in Midwest (
Identifiants
pubmed: 34094931
doi: 10.3389/fonc.2021.644885
pmc: PMC8170083
doi:
Types de publication
Journal Article
Langues
eng
Pagination
644885Informations de copyright
Copyright © 2021 Al Hussein Al Awamlh, Patel, Ma, Calaway, Ponsky, Hu and Shoag.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2016 Jun 20;34(18):2182-90
pubmed: 26884580
Cancer. 2018 Jan 1;124(1):55-64
pubmed: 28902401
JAMA Surg. 2017 Oct 1;152(10):978-980
pubmed: 28636713
Science. 1973 Dec 14;182(4117):1102-8
pubmed: 4750608
Clin Prostate Cancer. 2004 Jun;3(1):31-7
pubmed: 15279688
JAMA Intern Med. 2014 Sep;174(9):1450-9
pubmed: 25023650
Eur Urol. 2018 Dec;74(6):704-707
pubmed: 30177290
JAMA. 2019 Feb 19;321(7):704-706
pubmed: 30743264
JAMA Oncol. 2017 Oct 1;3(10):1393-1398
pubmed: 27768168
JAMA Netw Open. 2020 Dec 1;3(12):e2031349
pubmed: 33369661
J Urol. 2017 Feb;197(2):342-349
pubmed: 27596691
J Natl Compr Canc Netw. 2018 May;16(5S):620-623
pubmed: 29784740
Eur Urol. 2020 Jun;77(6):683-686
pubmed: 32098730
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):179-183
pubmed: 31591454
N Engl J Med. 2019 Dec 26;381(26):2581-2582
pubmed: 31881146
N Engl J Med. 1992 Apr 23;326(17):1102-7
pubmed: 1552911
J Clin Oncol. 2014 Nov 10;32(32):3667-72
pubmed: 25287826
Eur Urol. 2020 Sep;78(3):335-344
pubmed: 31980309
Ann Intern Med. 1998 Sep 1;129(5):412-6
pubmed: 9735070
J Urol. 2016 Sep;196(3):721-6
pubmed: 26946161
Cancer Causes Control. 2001 Oct;12(8):703-11
pubmed: 11562110